SecurityMDVX / Medovex Corp. (58504H101)
IndustrySurgical and Medical Instruments and Apparatus
Common Stock Shares Outstanding23,473,314 shares (as of 2018-06-30)
Total Insiders16
Total Directors11
Total Officers5

Stock Insider Trading (from SEC Form 4)

Medovex Corp. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

MDVX / Medovex Corp. insiders include Lawson James Ronald JR, Hennies Clyde A., Moon Dennis Glenn, Thomas John C, ANDREWS JAMES R M D, GORLIN STEVE, Mogford Jon, Kullmann Patrick C, and PAPASAN LARRY W, Hills Thomas Edward Gorlin Jarrett S, Crowne Jesse, Sablowski Manfred, Haufe Scott, Betz Randal R, Wright Jeffery Scott, .

Insider Roster

Insider Dir Off 10% Shares Owned
Crowne Jesse Director
X 210,747
Betz Randal R Director
X 181,027
Thomas John C Director
X 115,960
Mogford Jon Director
X 16,840
ANDREWS JAMES R M D Director
X 131,348
Hennies Clyde A. Director
X 131,348
GORLIN STEVE
1,640,704
Haufe Scott Director
X 1,031,782
Lawson James Ronald JR Director
X 18,256
PAPASAN LARRY W Director
X 228,136
Gorlin Jarrett S CHIEF EXECUTIVE OFFICER, Director
X X 662,172
Moon Dennis Glenn EXECUTIVE VICE PRESIDENT
X
Sablowski Manfred VP OF SALES AND MARKETING
X
Kullmann Patrick C COO, PRESIDENT
X
Wright Jeffery Scott CHIEF FINANCIAL OFFICER
X
Hills Thomas Edward Director
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-01-11 4 Crowne Jesse A D 0.550 10,407 210,747
2018-01-03 4 Crowne Jesse A D 0.550 4,093 200,340
2017-12-29 4 Betz Randal R A D 0.521 350 181,027
2017-12-29 4 Betz Randal R A D 0.558 9,650 180,677
2017-12-15 4 Mogford Jon P D 0.70 -1,000 16,840 11,788
2017-12-15 4 Thomas John C P D 0.70 -6,000 115,960 81,172
2017-10-30 4 Thomas John C A D 1.17 12,821 109,960
2017-10-30 4 PAPASAN LARRY W A D 1.17 12,821 228,136
2017-10-30 4 Mogford Jon A D 1.17 12,821 15,840
2017-10-30 4 Betz Randal R A D 1.17 12,821 164,837
2017-10-30 4 Lawson James Ronald JR A D 1.17 12,821 18,256
2017-10-30 4 Haufe Scott A D 1.17 12,821 1,031,782
2017-10-30 4 Crowne Jesse A D 1.08 31,240 200,340
2017-10-30 4 Crowne Jesse A D 1.17 2,137 169,100
2017-10-30 4 GORLIN STEVE A D 1.17 10,684 1,640,704
2017-10-30 4 Hennies Clyde A. A D 1.17 12,821 131,348
2017-10-30 4 ANDREWS JAMES R M D A D 1.17 12,821 131,348
2017-09-19 4 Haufe Scott S D 1.18 -20,000 1,018,961 1,202,374
2017-09-18 4 Haufe Scott S D 1.19 -50,000 1,038,961 1,236,364
2017-08-21 4 GORLIN STEVE P D 1.25 50,000 1,630,020 2,037,525
2017-08-16 4 GORLIN STEVE P D 0.90 200,000 1,580,020 1,422,018
2017-07-14 4 Betz Randal R P D 0.91 10,989 152,016 138,335
2017-06-28 4 GORLIN STEVE P D 0.88 2,000 1,380,020 1,214,418
2017-06-28 4 GORLIN STEVE P D 0.87 3,000 1,378,020 1,198,877
2017-06-19 4 Gorlin Jarrett S P D 0.90 20,000 662,172 595,955
2017-06-14 4 GORLIN STEVE P D 0.97 5,000 1,375,020 1,333,769
2017-06-07 4 GORLIN STEVE P D 0.98 5,000 1,370,020 1,342,620
2017-06-07 4 GORLIN STEVE P D 0.96 5,000 1,365,020 1,310,419
2017-06-07 4 GORLIN STEVE P D 0.95 15,000 1,360,020 1,292,019
2017-06-07 4 GORLIN STEVE P D 0.94 5,000 1,345,020 1,264,319
2017-06-06 4 Gorlin Jarrett S P D 0.94 5,000 642,172 603,642
2017-06-06 4 Gorlin Jarrett S P D 0.92 5,000 637,172 586,198
2017-06-06 4 Gorlin Jarrett S P D 0.91 5,000 632,172 575,277
2017-06-06 4 Gorlin Jarrett S P D 0.90 5,000 627,172 564,455
2017-06-06 4 Gorlin Jarrett S P D 0.89 5,000 622,172 553,733
2017-04-18 4 Haufe Scott P D 1.25 50,000 1,088,961 1,361,201
2017-03-28 4 Haufe Scott P D 1.29 250,612 1,038,961 1,340,260
2017-02-09 4 Gorlin Jarrett S P D 1.04 67,307 617,172 641,859
2017-02-09 4 GORLIN STEVE P D 1.04 144,230 1,340,020 1,393,621
2017-01-12 4 PAPASAN LARRY W A D 1.38 21,739 217,815
2017-01-12 4 Thomas John C A D 1.38 21,739 97,139
2017-01-12 4 Betz Randal R A D 1.38 21,739 141,027
2017-01-12 4 Haufe Scott A D 1.38 21,739 826,847
2017-01-12 4 Hennies Clyde A. A D 1.38 21,739 121,027
2017-01-12 4 Lawson James Ronald JR A D 1.38 5,435 5,435
2017-01-12 4 Mogford Jon A D 1.38 3,019 3,019
2017-01-12 4 ANDREWS JAMES R M D A D 1.38 21,739 121,027
2016-12-01 4 GORLIN STEVE P D 1.75 314,286 1,018,592 1,782,536
2016-12-01 4 GORLIN STEVE P D 1.75 -257,143 704,360 1,232,630
2016-04-19 4 Gorlin Jarrett S P D 1.225 44,081 561,118 687,370
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...